CN105996053A - 用于养发护发的营养组合物及其应用 - Google Patents
用于养发护发的营养组合物及其应用 Download PDFInfo
- Publication number
- CN105996053A CN105996053A CN201610514742.5A CN201610514742A CN105996053A CN 105996053 A CN105996053 A CN 105996053A CN 201610514742 A CN201610514742 A CN 201610514742A CN 105996053 A CN105996053 A CN 105996053A
- Authority
- CN
- China
- Prior art keywords
- hair care
- hair
- nutritional composition
- alpha
- linoleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 235000016709 nutrition Nutrition 0.000 title abstract description 8
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 44
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 22
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 22
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 19
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000004472 Lysine Substances 0.000 claims abstract description 19
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910052802 copper Inorganic materials 0.000 claims abstract description 19
- 239000010949 copper Substances 0.000 claims abstract description 19
- 239000011701 zinc Substances 0.000 claims abstract description 19
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 19
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims abstract description 18
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims abstract description 17
- 229960003067 cystine Drugs 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 230000006870 function Effects 0.000 abstract description 8
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 abstract description 6
- 235000020778 linoleic acid Nutrition 0.000 abstract description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 235000015097 nutrients Nutrition 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 5
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000002503 metabolic effect Effects 0.000 abstract description 3
- 230000004888 barrier function Effects 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 230000003752 improving hair Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 210000002390 cell membrane structure Anatomy 0.000 abstract 1
- 230000019522 cellular metabolic process Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 230000009897 systematic effect Effects 0.000 abstract 1
- 239000005495 thyroid hormone Substances 0.000 abstract 1
- 229940036555 thyroid hormone Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 201000004384 Alopecia Diseases 0.000 description 8
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 8
- 231100000360 alopecia Toxicity 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 235000003935 Hippophae Nutrition 0.000 description 5
- 241000229143 Hippophae Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000003648 hair appearance Effects 0.000 description 5
- 230000037308 hair color Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 4
- 229960004232 linoleic acid Drugs 0.000 description 4
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000003814 hair luster Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 244000268590 Euryale ferox Species 0.000 description 2
- 235000006487 Euryale ferox Nutrition 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000002378 plant sterols Nutrition 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种用于养发护发的营养组合物及其应用,包括以下组分:2~5mg铜、15~25mg锌、2~4g α‑亚麻酸、4~8g亚油酸、500~1000mg VC、0.6~5g赖氨酸或/和胱氨酸;通过补充机体营养物质,α‑亚麻酸和亚油酸不仅作为输送营养物质的载体,而且具有增强细胞膜结构,维持和修复屏障作用,抗炎和抗氧化,与其他组分协同作用,增强机体体质,维持细胞和分子的正常代谢,调节甲状腺激素,促进和调节人体代谢,恢复人体正常肝肾功能及代谢机制,从内而外对人体进行系统调理,从根本上改善发质,促进头发的生长,使头发乌黑亮丽,光滑、润泽并弹性。
Description
技术领域
本发明涉及一种保健食品,特别涉及一种用于养发护发的营养组合物及其应用。
背景技术
随着经济的发展,现代生活节奏的加快和生活压力的剧增,脱发、落发以及过早地出现白发等一系列头发疾病的发病率也越来越高,给现代人的生活带了越来越多的困扰。这些头发问题不仅影响美观,还会使患者的心理产生自卑、抑郁等不良情绪,从而使正常的工作、生活和社交活动都受到影响。而不同的健康隐患会导致头发出现相应的问题:(1)甲状腺机能亢进,导致有损发质造成脱发;(2)甲状腺机能减退,可能使发质变脆而干枯;(3)营养不良或贫血,造成掉发过多;(4)神经内分泌系统紊乱,头发大量脱落。
发明内容
有鉴于此,本发明的目的在于提供一种用于养发护发的营养组合物及其应用,通过补充机体营养物质,增强机体体质,维持细胞和分子的正常代谢,调节甲状腺激素,促进和调节人体代谢,恢复人体正常肝肾功能及代谢机制,从内而外对人体进行系统调理,从根本上改善发质,促进头发的生长,使头发乌黑亮丽,光滑、润泽并弹性。
本发明的用于养发护发的营养组合物,包括以下组分:2~5mg铜、15~25mg锌、2~4gα-亚麻酸、4~8g亚油酸、500~1000mg VC、0.6~5g赖氨酸或/和胱氨酸。
进一步,包括以下组分:3~5mg铜、18~25mg锌、2~4gα-亚麻酸、4~8g亚油酸、600~900mg VC VC、0.6~4g赖氨酸或/和胱氨酸;
进一步,包括以下组分:4mg铜、22mg锌、3gα-亚麻酸、6g亚油酸、800mgVC VC、2g赖氨酸或/和胱氨酸。
进一步,可加入药学、保健品学、食品学上能够接受的载体制成制剂。
本发明的用于养发护发的营养组合物在制备养发护发的药品,保健品、食品上的应用。
本发明的有益效果:本发明的用于养发护发的营养组合物及其应用,通过补充机体营养物质,α-亚麻酸和亚油酸不仅作为输送营养物质的载体,而且具有增强细胞膜结构,维持和修复屏障作用,抗炎和抗氧化,于其他组分协同作用,增强机体体质,维持细胞和分子的正常代谢,调节甲状腺激素,促进和调节人体代谢,恢复人体正常肝肾功能及代谢机制,从内而外对人体进行系统调理,从根本上改善发质,促进头发的生长,使头发乌黑亮丽,光滑、润泽并弹性。
胱氨酸:作为一种含硫氨基酸,具有促进细胞氧化还原功能,使肝功能旺盛,并能中和毒素、促进白细胞增生、阻止病原菌发育的作用,参与毛发的生长,胱氨酸代谢紊乱或缺乏时,会导致脱发。
铜:作为人体必需的微量元素之一,在机体内大部分以有机复合物形式存在,很多是金属蛋白,以酶的形式发挥功能。通过含铜酶参与维持中枢神经系统正常功能、促进黑色素形成及维护毛发正常结构。
α-亚麻酸:作为人体的必需脂肪酸,是磷脂的重要组成部分,维持细胞的结构完整和功能正常,对维持大脑和神经细胞的正常功能具有重要作用,此外具有促进血浆低密度脂蛋白(LDL)向高密度脂蛋白(HDL)转化,降低LDL,升高HDL的作用,进而降低血脂,对动脉粥样硬化、心脑血管疾病具有保护作用;α-亚麻酸及其代谢产物EPA和DHA能够抑制T细胞及其他细胞产生前炎性细胞因子如IL-1、IL-2、IL-6和TNF-a等,因此具有抗炎功能;此外还具有抗肿瘤、提高免疫力的作用。
锌:具有重要的生理功能和营养作用,参与酶的合成,在内分泌系统功能方面,锌影响肾上腺皮质激素、胰岛素生物合成;缺锌会影响内分泌系统的协调,导致患者脱发症。
亚油酸:作为人体的必需脂肪酸,与动物的精子形成有关,研究发现,如果膳食中长期缺乏亚油酸,动物试验证明可出现不孕症,受精进程也发生障碍。具有降低胆固醇的作用;通过抑制黏附分子、趋化因子和细胞介素等产生,具有抗炎的作用;而这些因子也参与动脉粥样硬化过程的关键分子,因此,也具有保护心血管疾病作用。改善胰岛素敏感性,抑制胰腺癌细胞的增殖、迁移和促进其凋亡,起到抗癌作用。此外亚油酸是组织细胞的组成成分,特别是参与线粒体及细胞膜磷脂的合成。对维持皮肤和神经、大脑细胞的生长分化具有重要作用。如亚油酸缺乏可导致线粒体肿胀、细胞膜结构、功能改变、膜透性、脆性增加,导致皮肤出现湿疹。
VC作为电子供体具有抗氧化,还是强还原剂,它作为体内维持羟化酶活性所必需的辅助因子,参与体内许多重要物质的合成与代谢,如胶原蛋白、5-羟色胺、去甲肾上腺素等,此外还具有解毒、提高机体抵抗力的作用。
赖氨酸:赖氨酸是肽激素和辅酶的前身物之一,它能促进体内丙酮酸的代谢,使其进一步氧化生成乙酰辅酶A,利于神经组织中的乙酰胆碱合成,促进神经递质的代谢而兴奋神经中枢。此外,赖氨酸可提高血中SOD活性,降低血中氧自由基含量,起到抗氧化作用。
另外,还可加入5-10mg的人参、当归、侧柏叶、红花、芡实、茯苓、川芎以增加养发护发效果。可加入6-15mg的植物甾醇、丹皮酚、,促进皮肤毛囊细胞的生长,为皮肤和头发输送养分,改善头皮微循环,还可加入5-8mg的沙棘子油,促进细胞组织再生及新陈代谢,营养毛发。
具体实施方式
实施例一
本实施例的用于养发护发的营养组合物,包括以下组分:2mg铜、15mg锌、2gα-亚麻酸、4g亚油酸、500mg VC、2g赖氨酸。
实施例二
本实施例的用于养发护发的营养组合物,包括以下组分:5mg铜、25mg锌、4gα-亚麻酸、8g亚油酸、1000mg VC、900mg胱氨酸。
实施例三
本实施例的用于养发护发的营养组合物,包括以下组分:3mg铜、18mg锌、2gα-亚麻酸、4g亚油酸、600mg VC、1g赖氨酸和600mg胱氨酸。
实施例四
本实施例的用于养发护发的营养组合物,包括以下组分:5mg铜、25mg锌、4gα-亚麻酸、8g亚油酸、900mg VC、2g赖氨酸和600mg胱氨酸。
实施例五
本实施例的用于养发护发的营养组合物,包括以下组分:3mg铜、25mg锌、2gα-亚麻酸、8g亚油酸、800mg VC、2g赖氨酸和900mg胱氨酸。
实施例六
本实施例的用于养发护发的营养组合物,包括以下组分:4mg铜、22mg锌、3gα-亚麻酸、6g亚油酸、800mg VC VC、1.2g赖氨酸和800mg胱氨酸。
实施例七
包括以下组分:2mg铜、25mg锌、2gα-亚麻酸、8g亚油酸、500mg VC VC、5g赖氨酸或/和胱氨酸、5mg的人参、5mg当归、5mg侧柏叶、5mg红花、5mg芡实、5mg茯苓、5mg川芎、6mg的植物甾醇、6mg丹皮酚、5mg的沙棘子油。
实施例八
包括以下组分:5mg铜、15mg锌、4gα-亚麻酸、4g亚油酸、1000mg VC、0.6g赖氨酸或/和胱氨酸、10mg的人参、15mg的丹皮酚、8mg的沙棘子油。
实施例九
包括以下组分:3mg铜、25mg锌、2gα-亚麻酸、8g亚油酸、700mg VC、4g赖氨酸或/和胱氨酸、6mg的当归、6mg红花、6mg茯苓、12mg的植物甾醇、5mg的沙棘子油。
实施例十
包括以下组分:5mg铜、18mg锌、4gα-亚麻酸、4g亚油酸、900mg VC、0.6g赖氨酸或/和胱氨酸、10mg的侧柏叶、6mg的丹皮酚、5mg的沙棘子油。
上述实施例中,可加入药学、保健品学、食品学上能够接受的载体制成制剂。可以通过添加本领域使用的任何辅料制备成适合的剂型。所述的辅料包括但不限于崩解剂、填充剂、润滑剂、润湿剂、增溶剂、助溶剂、乳化剂、着色剂、黏合剂、渗透压、调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗黏着剂、抗氧剂、抗氧增效剂、鳌合剂、渗透促进剂、pH调节剂、增塑剂、表面活性剂、发泡剂、消泡剂、增稠剂、包合剂、保湿剂、吸收剂、稀释剂、絮凝剂与反絮凝剂、助滤剂等。
将上述实施例的用于改善记忆力的功能型营养组合物在制备养发护发的药品,保健品、食品上的应用。
实验例1
李××,女,35岁,头发枯黄暗哑,无光泽,近一年来大量掉头发,每日取1袋本发明实施例1制备的用于养发护发的营养组合物食用,连续食用90天后,不再大量掉发,发色转黑,且有光泽。
实验例2
杨×,女,27岁,由于经常烫发,致使发质受损、枯燥,发色暗黄,且易掉发,每日取1袋本发明实施例2制备的用于养发护发的营养组合物食用,连续食用80天后,发质变好,发色乌黑,有光泽,不易掉发。
实验例3
蒋××,男,46岁,近几年前额头发稀疏,头发色泽较黄。每日取1袋本发明实施例5制备的用于养发护发的营养组合物食用,连续食用100天后,前额头发变浓密,头发颜色转黑,有光泽。
实验例4
何×,男,30岁,头发色泽偏黄,无光泽。每日取1袋本发明实施例6制备的用于养发护发的营养组合物食用。连续食用82天后,头发转乌黑且有光泽。
实验例5
张××,男,县人,22岁,头发颜色发黄,暗淡无光。每日取1袋本发明实施例7制备的用于养发护发的营养组合物食用,连续食用86天后,发色转黑,有光泽。
实验例6
刘××,女,县人,44岁,头发枯黄,暗淡无光泽。每日取1袋本发明实施例4制备的用于养发护发的营养组合物食用,连续食用60天后,头发变乌黑,且光泽度好。
实验例7
伍×,男,38岁,头发色泽暗黄、枯燥,无光泽。每日取1袋本发明实施例4制备的用于养发护发的营养组合物食用,。连续食用85天后,头发颜色转黑,有光泽。
最后说明的是,以上实施例仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的宗旨和范围,其均应涵盖在本发明的权利要求范围当中。
Claims (5)
1.一种用于养发护发的营养组合物,其特征在于:包括以下组分:2~5mg铜、15~25mg锌、2~4gα-亚麻酸、4~8g亚油酸、500~1000mg VC、0.6~5g赖氨酸或/和胱氨酸。
2.根据权利要求1所述的用于养发护发的营养组合物,其特征在于:包括以下组分:3~5mg铜、18~25mg锌、2~4gα-亚麻酸、4~8g亚油酸、600~900mg VC、0.6~4g赖氨酸或/和胱氨酸。
3.根据权利要求1所述的用于养发护发的营养组合物,其特征在于:包括以下组分:4mg铜、22mg锌、3gα-亚麻酸、6g亚油酸、800mg VC、2g赖氨酸或/和胱氨酸。
4.根据权利要求1-3任一权利要求所述的用于养发护发的营养组合物,其特征在于:可加入药学、保健品学、食品学上能够接受的载体制成制剂。
5.根据权利要求1-3任一权利要求所述的用于养发护发的营养组合物在制备养发护发的药品,保健品、食品上的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610514742.5A CN105996053A (zh) | 2016-06-30 | 2016-06-30 | 用于养发护发的营养组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610514742.5A CN105996053A (zh) | 2016-06-30 | 2016-06-30 | 用于养发护发的营养组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105996053A true CN105996053A (zh) | 2016-10-12 |
Family
ID=57106878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610514742.5A Pending CN105996053A (zh) | 2016-06-30 | 2016-06-30 | 用于养发护发的营养组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105996053A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110025775A (zh) * | 2019-05-14 | 2019-07-19 | 连云港诗碧曼生物科技有限公司 | 一种温和固发的防脱发生发精华液及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1456212A (zh) * | 2003-01-15 | 2003-11-19 | 邬纯忠 | 一种生发与养发外用制剂的制备方法 |
CN1544038A (zh) * | 2003-11-17 | 2004-11-10 | 刘贤英 | 一种黑发生发保健药物及制备工艺 |
CN1816287A (zh) * | 2003-01-31 | 2006-08-09 | 宝洁公司 | 改善哺乳动物角质组织外观的方法 |
CN102627545A (zh) * | 2012-03-27 | 2012-08-08 | 安徽华佗国药股份有限公司 | 一种丹皮酚的提取方法 |
CN103800879A (zh) * | 2014-02-17 | 2014-05-21 | 杜志政 | 一种天然生乌发颗粒及其制备方法 |
-
2016
- 2016-06-30 CN CN201610514742.5A patent/CN105996053A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1456212A (zh) * | 2003-01-15 | 2003-11-19 | 邬纯忠 | 一种生发与养发外用制剂的制备方法 |
CN1816287A (zh) * | 2003-01-31 | 2006-08-09 | 宝洁公司 | 改善哺乳动物角质组织外观的方法 |
CN1544038A (zh) * | 2003-11-17 | 2004-11-10 | 刘贤英 | 一种黑发生发保健药物及制备工艺 |
CN102627545A (zh) * | 2012-03-27 | 2012-08-08 | 安徽华佗国药股份有限公司 | 一种丹皮酚的提取方法 |
CN103800879A (zh) * | 2014-02-17 | 2014-05-21 | 杜志政 | 一种天然生乌发颗粒及其制备方法 |
Non-Patent Citations (1)
Title |
---|
沈碧秋: "治疗脱发新药——养发胶囊", 《广州医学院学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110025775A (zh) * | 2019-05-14 | 2019-07-19 | 连云港诗碧曼生物科技有限公司 | 一种温和固发的防脱发生发精华液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101196523B1 (ko) | 천연물 발효 추출물을 유효성분으로 하는 발모제 조성물 | |
CN104041828A (zh) | 黑枸杞美白祛斑片 | |
JP2012171901A (ja) | 男性用の発毛および育毛用経口摂取食品 | |
CN103025307A (zh) | 菊苣酸及衍生物用于调节皮肤色素沉着的用途 | |
KR20100022137A (ko) | 녹용을 포함하는 발효 한방 생약 추출물을 함유한 탈모방지용 화장품 샴푸 제조방법 및 샴푸 | |
CN106309340A (zh) | 一种柚子汁抗皱去纹护肤配方 | |
KR101541533B1 (ko) | 탈모 방지, 발모 촉진, 비듬 생성 억제 및 두피 염증 완화용 화장료 조성물 | |
Li et al. | An approach to the nature of Qi in TCM-Qi and bioenergy | |
CN104126744A (zh) | 黑枸杞延春美容片 | |
CN101791285B (zh) | 一种用于清除面部老年斑的黄皮酰胺复合纳米乳及其制备方法 | |
CN105996053A (zh) | 用于养发护发的营养组合物及其应用 | |
JP2009013083A (ja) | 経口投与組成物 | |
CN105030574A (zh) | 一种用于脸部护理的组合物 | |
CN105411908A (zh) | 一种含有熊果苷、桑叶提取物和薏苡仁提取物的美白化妆品 | |
CN105534858A (zh) | 植物精华粉及面膜霜和面膜粉 | |
CN107661272A (zh) | 元素香波 | |
CN107875065A (zh) | 一种滋润养颜的护肤品及其制备方法 | |
CN103784373A (zh) | 一种中药美白面膜制作方法 | |
CN106937923A (zh) | 灵芝花粉护肤防衰霜 | |
CN102793653A (zh) | 一种胎盘素美容液 | |
CN106390061A (zh) | 一种外用防脱、育发的毛囊干细胞唤醒因子的组合物及其制备方法 | |
JPH08291025A (ja) | 養毛料 | |
CN105168067A (zh) | 一种活力祛斑精华液及其制备方法 | |
JP2007037416A (ja) | 機能強化補助食品 | |
JP2007119433A (ja) | 酒粕エキスにイワベンケイエキス等を配合してなる、化粧料、健康食品等の有用素材 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |
|
RJ01 | Rejection of invention patent application after publication |